MedTrace Logo

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

NCT07072793 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 131005

Last updated 2026-02-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work.

The study compares two groups of participants who are confirmed to have mild-to moderated COVID-19 and who have high chances of the disease becoming severe.

The two groups are:

People who took the antiviral medication nirmatrelvir-ritonavir (also called Paxlovid) People who were eligible to receive antiviral medication but did not receive any.

The participants will be selected from various health databases in the US between June 2021 and December 2022.

The main goals are:

To look at the characteristics of both groups of participants with COVID-19. To measure how much work these participants missed, including days off and sick leave, and the costs associated with this work loss.

To compare work loss and costs between the two groups of participants, considering differences in their clinical and demographic characteristics.

The study will evaluate at least 30 days of data from participants after they are confirmed to have COVID-19

Conditions

  • COVID-19 (Coronavirus Disease 2019)

Interventions

DRUG

nirmatrelvir-ritonavir

Participants with confirmed diagnosis of Covid-19 and with mild to moderate symptoms at high-risk for progressing to severe disease

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-31
Primary Completion
2024-11-15
Completion
2024-11-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07072793 on ClinicalTrials.gov